A medical device for the selective dissection of pathological tissues and fibrosis

Projektinformationen

CADISS

ID Finanzhilfevereinbarung: 882323

DOI

10.3030/882323

Projekt abgeschlossen

EK-Unterschriftsdatum 4 November 2019

Startdatum 1 Dezember 2019

Enddatum 31 März 2020

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

AUXIN SURGERY
Belgium

Periodic Reporting for period 1 - CADISS (A medical device for the selective dissection of pathological tissues and fibrosis)

Berichtszeitraum: 2019-12-01 bis 2020-03-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

More than 10% of surgical procedures involve critical dissection steps whereby the pathological tissue is carefully separated from the healthy surrounding tissues. Despite the importance of selective dissection in surgical procedures, the current tools are sub-optimal because they are all still relying either on tearing force or on non-selective cutting, which frequently damage critical organs such as nerves, muscles and other organs.
The CADISS System is a novel method of dissection in general surgery based on the combination of mechanical surgery instruments with the topical deposition of a drug, which selectively facilitates separation of pathological tissues without using cutting instruments.
This feasibility study confirms the feasibility of the project in all technical, commercial and financial aspects. The main activities to be carried out include the development of new surgical tools, carrying out the required regulatory processes and scaling up production. We estimate an investment of €9.3M with €3.2M from the Grant support of the Accelerator Pilot SME Instrument and €6.1M from the equity finance under the EIC.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

TECHNICAL FEASIBILITY. We have assessed the feasibility of our product development and regulatory strategy which includes pre-clinical and clinical studies.
COMMERCIAL FEASIBILITY. We have assessed our Freedom to Operate and the regulatory procedure in the EU and the USA. Our commercial analysis includes analysis of the market, end-users, drivers and barriers. We have also defined our commercial strategy.
FINANCIAL FEASIBILITY. We have performed the funding needs validation, delineated the cost structure and 5 years business projections. We will generate a big turnover and profit, reaching breakeven in 2023.
The Feasibility Study confirms the technical feasibility and commercial profitability of our project. Moreover, it shows the novelty of our innovation and the great benefits that would bring to patients and the health sector.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Currently there is no effective solution for facilitating the dissection of pathological tissues that will successfully avoid unwanted damage during surgery. The CADISS system will have a big impact on 1) surgeons, providing an effective tool, 2) health systems and insurance companies, reducing the high associated costs, 3) patients and their relatives quality of life, and 4) our company´s growth.

image1.png